
    
      Aspirin in patients with dukes C or high risk dukes B colorectal cancer can improve survival
      in this patient population over placebo control.

      Eligible patients will be randomized to treatment arms, using the following stratification
      factors:

        -  Study Centre

        -  Tumour Type

        -  Type of adjuvant chemotherapy received(exposed/not exposed to oxaliplatin

      Patients will be randomized over a 5 years' time period. After randomization, patient will
      have 3 monthly assessments with treatment for 3 years followed by 6 monthly assessments for
      additional 2 years follow-up
    
  